Riskpilot← Back to searchSign inGet full accessEriPharma AB
ABActiveOrg 5592523962Economic activity was not specified by tax authority · NACE 0000Est. 20200 employees
Revenue 2024
SEK 0
EBITDA margin
—
-1% vs 2023
Equity ratio
24.7%
Financial strength
Net profit 2024
SEK 32K
+1% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -42K | -1% |
| Net profit | SEK 32K | +1% |
| Total assets | SEK 1,7M | +35% |
| Equity | SEK 425K | +370% |
| Employees | 0 | — |
Legal name
EriPharma AB
Org number
5592523962
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
16 april 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att förvalta aktier i bolag som bedriver apoteksverksamhet, handel med värdepapper samt att, direkt eller indirekt, äga och förvalta övrig fast och lös egendom och därmed förenlig verksamhet.
Address
Email
6bjhgsxbp@kivramail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −12 | −10 | −27 | −42 | −42 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | −12 | −10 | −27 | −42 | −42 |
| Net financials | — | — | −17 | −27 | −27 |
| Profit before tax | −12 | −10 | −44 | 32 | 32 |
| Tax | −0 | −0 | — | — | −0 |
| Net profit | −12 | −10 | −44 | 32 | 32 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 304 | 304 | 1 180 | 1 278 | 1 722 |
| Equity | 13 | 53 | 59 | 90 | 425 |
| Long-term debt | 0 | 0 | 710 | 1 038 | 1 018 |
| Short-term debt | 291 | 251 | 412 | 150 | 280 |
| Total debt | 291 | 251 | 1 121 | 1 188 | 1 298 |
EBITDA margin
-4200000.0%
This company
15.8%
Market median
-26582378% vs market
20202024
Equity ratio
24.7%
This company
38.2%
Market median
-35% vs market
20202024
Return on equity
7.5%
This company
18.4%
Market median
-59% vs market
20202024
Net profit margin
3200000.0%
This company
8.1%
Market median
+39506073% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
3.05×
This company
0.62×
Market median
-392% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA | Audit | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EriPharma AB 
GF Apoteksinvest ABBoard members of EriPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Anders Gyllenberg | Audit | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Yohannes Girmay Yohannes | Board of Directors | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Sara Ghirmay Drar | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |